Vanguard Global Advisers’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Vanguard Global Advisers’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-154,061	Closed	-$38.1K	–	3722
2026 Q1	$38.1K	Buy	+154,061	New	+$61.3K	﹤0.01%	3129

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Vanguard Global Advisers's SGMO Position: Q2 2026 in Review

Vanguard Global Advisers sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 154,061 shares — an estimated $38.1K sold.

Vanguard Global Advisers first reported a position in SGMO in Q1 2026 and held it in 1 quarter. The position peaked at $38.1K in Q1 2026. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Vanguard Global Advisers reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 154,061 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $38.1K.
Vanguard Global Advisers first reported a position in SANGAMO THERAPEUTICS INC in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's SANGAMO THERAPEUTICS INC position peaked at $38.1K in Q1 2026.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.